Providers who treat young people with psychosis must navigate a host of issues unique to this population, including confidentiality and consent rules, the role of the family, and support from schools, according to Steven Adelsheim, MD, clinical professor of psychiatry and behavioral sciences, Stanford University School of Medicine.
Providers who treat young people with psychosis must navigate a host of issues unique to this population, including confidentiality and consent rules, the role of the family, and support from schools, according to Steven Adelsheim, MD, clinical professor of psychiatry and behavioral sciences, Stanford University School of Medicine.
Transcript
What are the special considerations for working with adolescents with psychosis as opposed to adults?
Some of the special issues for adolescents really include things like informed consent and confidentiality; different states have different rules about when young people can engage in their own treatment, per se. There are also issues around interfacing with families in terms of, how do we support that young [person] that is really developing and moving towards independence, to be able to get the support they feel they need around their own symptoms in a positive and supportive way, while also recognizing they’re usually living within some kind of identified family unit that also is very concerned and worried about them and wants to also guide their care. So negotiating those issues around the early treatment, where that young person can feel like they have a voice in their own care while also reassuring and working with their families, and dealing with actually the communication issues become very critical in terms of that support.
One other area that’s really important is around schools and secondary schools. For young people with a psychotic illness, it becomes very important to be able to deal with their schools, whether it’s around special education support or section 504 to have accommodations in classroom settings, are also really unique issues in supporting adolescents with psychotic illness.
GLP-1 Receptor Agonists Reduce Adverse Cardiovascular Outcomes, Improve Survival
August 2nd 2025Studies found that glucagon-like peptide-1 (GLP-1) receptor agonists were valuable tools in improving outcomes and survival in those with coronary plaque and after ST-elevation myocardial infarction.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
AI, GLP-1s Among Topics to Be Discussed During ASPC Annual Meeting
July 28th 2025The American Society for Preventive Cardiology (ASPC) Congress on Cardiovascular Disease Prevention features multiple sessions on different methods of treating and preventing cardiovascular disease, including through the use of artificial intelligence (AI) and glucagon-like peptide-1 (GLP-1) receptor agonists.
Read More